Industrial, Manufacturing & Heavy Industry Market News

Insights into netupitant-palonosetron FDC market made available by top research firm

Industrial Market Research

Netupitant is a novel and a NK1 receptor antagonist, and palonosetron is a second-generation 5-HT3 receptor antagonist. While netupitant was not available in the drug market earlier, palonosetron drugs were already present under trade names Paloxi, Onicit, and Aloxi.

The fixed dose combination (FDC) of netupitant and palonosetron market is a product proposed for the treatment of the most common side effects of chemotherapy-nausea and vomiting. The product is currently in its third stage of trial.

The combination drug is expected to overcome major problems associated with the current mode of treatment of the CINV condition, which involves the use of 5-HT3 receptor antagonists.

The netupitant-palonosetron FDC market is driven by rise in number of patients who undergo chemotherapy. The market is segmented on the basis of patient pool and geography.

Currently, pharmaceutical companies are increasingly investing in the further discovery of FDC drugs to achieve increased industry leading breadth and depth of clinical research.

Request for Sample Copy@

However, factors such as adverse effect of netupitant-palonosetron FDC and high cost of drugs for patients act as restraints for the growth and development of the market. The new approaches and advancement in netupitant-palonosetron FDC market is the development in efficacy and potential of new FDC drugs.

The foundation of combination therapy is projected to build up in broad spectrum. Netupitant‐palonosetron, by trade name of Akynzeo, is approved and witnesses an increasing traction in the U.S.

and European region.

The classes of drugs used in the treatment of CINV are 5-HT3 receptor antagonists, NK1 receptor antagonists, corticosteroids, dopamine antagonists, benzodiazepines, and cannabinoids. However, Akynzeo is mostly used in the treatment, and is helpful in the prevention of nausea and vomiting due to long-lasting action, with no major adverse effects.

Geographically, the global netupitant-palonosetron FDC market is segmented into North America, Europe, Asia-Pacific, and LAMEA. In terms of growth rate, Asia-Pacific is expected to remain dominant over the forecast period, followed by Europe.

North America, on the other hand, is expected to increase at a steady pace due to its steady growth in number of cancer patients opting for chemotherapy.

Major players profiled in the report includes Helsinn Holding S.A., Heron Therapeutics, Inc., Eisai Pharmaceutical Pvt. Ltd., and Tesaro, Inc.

Enquire about report@


  • This report provides an extensive analysis of the current & emerging market trends and dynamics in the global netupitant‐palonosetron FDC market.
  • This report entails the detailed quantitative analysis of the current trends and future estimations from 2014 to 2022, which assists to identify the prevailing market opportunities.
  • This study evaluates competitive landscape and value chain to understand the competitive environment across the geographies.
  • Comprehensive analysis of factors that drive and restrict the growth of the market is provided.


News From

Big Market Research - Market Research ReportsBig Market Research
Category: Market Research Publishers and RetailersCompany about: With the arsenal of different search reports, we help you here to look and buy research reports that will be helpful to you and your organization. Our research reports have the capability and authenticity to support your organization for growth and consistency. With the window of opportunity getting open and shut at a speed of light, it has become very important to survive in the market and only the fittest and competent enough can do so. So, we try and provide with latest changes in the market ...
This email address is being protected from spambots. You need JavaScript enabled to view it.